Network meta-analysis on efficacy and safety of different biologics for ulcerative colitis

BMC Gastroenterology

Table 2 SUCRA score for clinical remission, clinical response, endoscopic improve, mucosal healing, adverse events, recurrence of ulcerative colitis, infections, adverse events resulting in treatment discontinuation, serious adverse events, serious infections in induction treatments

Clinical remission		Clinical response		Endoscopic improve		Mucosal Healing		Adverse events		Recurrence of ulcerative colitis		Infections		Adverse events resulting in treatment discontinuation		serious adverse events		serious infections
Vedoli	94.1	Vedoli	97.5	Usteki	94.4	Inflix + AZA	92.2	Cobit	88.4	Guselku	94.9	Etrol	72.5	Guselku	94.8	Guselku	78.0	Elde	65.3
Inflix + AZA	80.1	Inflix + AZA	92.7	Etrol	69.1	Inflix	91.4	Guselku	81.7	Usteki	65.6	Placebo	67.4	Golimu	77.8	Elde	75.1	Etrol	64.8
Adal	72.9	Inflix	86.9	Adal	59.6	Adal	74.1	Usteki	64.2	Adal	62.5	Guselku	64.0	Cobit	67.4	Usteki	74.4	Usteki	58.7
PF-00547659	71.7	Usteki	75	Placebo	19.4	Etrol	71.5	Etrol	61.8	Dacl	6.6	Usteki	60.4	Usteki	58.0	Golimu	66.1	Golimu	51.6
Usteki	62.6	Golimu	71.4	Cobit	7.6	AZA	64.5	Elde	53.7	Etrol	58.9	Adal	55.0	Placebo	50.7	Adal	61.3	Guselku	51.2
Etrol	60.9	PF-00547659	59.7			BMS-936557	50.3	Placebo	53.2	PF-00547659	53.1	PF-00547659	45.9	PF-00547659	47.5	Cobit	41.5	Adal	48.6
AZA	57.5	BMS-936557	56			Visil	44.2	Golimu	45.5	Golimu	48.4	Elde	42.7	Adal	34.8	Visil	39.1	Placebo	34.7
Cobit	57.4	Elde	50.3			Elde	43.4	Adal	43.7	Cobit	31.9	Golimu	25.0	Basil	27.9	Placebo	37.3	BMS-936557	25.0
Inflix	57.3	AZA	48.9			Basil	36.7	Basil	39.8	Placebo	28.1	BMS-936557	16.9	Etrol	22.6	PF-00547659	37.1
Golimu	47.9	Etrol	45			Placebo	33.9	PF-00547659	36.2					BMS-936557	18.6	Etrol	29.7
Elde	41.6	Adal	43.8			Golimu	26.8	BMS-936557	31.4							BMS-936557	10.4
Guselku	34.1	Guselku	37.5			PF-00547659	15.1	Visil	0.3
BMS-936557	28.9	Visil	35.5			Guselku	5.8
Basil	25.4	Placebo	17.6
Visil	24.2	Basil	15.1
Placebo	21	Cobit	14.5
Dacl	12.3	Dacl	2.7

ISSN: 1471-230X